Peptides: Side Effects Overview by Class

Side effects in the peptide class are not uniform — they vary substantially based on mechanism of action, receptor targets, and route of administration. This overview covers the major peptide classes used for performance, recovery, and body composition purposes.

GH-Stimulating Peptides (GHRPs and GHRHs)

Water Retention

The most frequently reported side effect of GH-stimulating peptides (GHRP-2, GHRP-6, ipamorelin, CJC-1295, tesamorelin) is water retention. The mechanism is well understood: elevated GH stimulates hepatic IGF-1 production, and IGF-1 increases renal sodium and water reabsorption at the proximal tubule. The result is mild extracellular fluid expansion — most noticeable as facial puffiness, ankle swelling, or a soft, bloated appearance. This effect is dose-dependent and typically resolves within 3-7 days of stopping.

Hunger Stimulation (GHRP-6 specific)

GHRP-6 is a potent ghrelin receptor agonist. Ghrelin is the primary hunger hormone — its receptor activation triggers appetite stimulation as a direct on-mechanism effect, not a side effect of formulation. Users who want GH release without significant hunger should use ipamorelin, which has demonstrated selectivity for the GH secretagogue receptor with minimal ghrelin-receptor-mediated hunger effects.

Cortisol and Prolactin (GHRP-2 and GHRP-6, dose-dependent)

At higher doses, GHRP-2 and GHRP-6 can elevate cortisol and prolactin. This is dose-dependent — at typical research doses (100-200mcg per injection), cortisol and prolactin elevation is modest and transient. Ipamorelin does not demonstrate this effect at standard doses, which is one reason it is preferred by many researchers.

Insulin Resistance (Chronic GH Elevation)

Chronic supraphysiological GH elevation can impair insulin sensitivity. This is a known effect of exogenous GH therapy and likely extends to long-term, high-dose GH secretagogue use. For this reason, time-limited cycles are recommended rather than continuous indefinite use.

Side Effects by Peptide Class

Peptide Class	Common Side Effects	Mechanism	Dose-Dependent	Management
GHRP class (GHRP-2, GHRP-6)	Water retention, hunger, cortisol/prolactin elevation	Ghrelin receptor agonism; GH → IGF-1 → renal Na+ reabsorption	Yes — highest at doses >300mcg	Lower dose; cycle off; use ipamorelin instead
CJC-1295 / GHRH analogs	Water retention, fatigue at high doses	GHRH receptor agonism → sustained GH pulse	Moderate dose-dependence	Reduce dose; every-other-day protocol
Ipamorelin	Water retention (mild), minimal hunger	Selective GH secretagogue receptor; minimal ghrelin agonism	Low dose-dependence at 100-200mcg	Monitor; lower dose if water retention problematic
BPC-157	Nausea (some users), rare headache	Unknown — no characterized human mechanism	Unclear; animal data suggests good tolerance	Dose reduction; no established protocol adjustment
TB-500	Generally mild; theoretical Lyme-like symptoms (unconfirmed)	Actin-binding; systemic distribution	Unknown	Monitor; no established mitigation
GLP-1 agonists (semaglutide)	Nausea, vomiting, diarrhea (~40% at initiation)	GLP-1 receptor in GI tract slows gastric emptying	Yes — worse at higher doses or rapid escalation	Slow escalation protocol; antiemetics if needed
GHK-Cu (topical)	Minimal; rare contact dermatitis	Local copper delivery; topical application	Very low	Patch test; discontinue if rash occurs

BPC-157 and TB-500

BPC-157 is generally described as well-tolerated in the animal literature. Some human users report nausea, particularly at higher doses or when taken orally. Headache has been reported anecdotally. No serious adverse events have been formally documented in humans because no formal human safety trials exist — which is itself a data gap, not a safety endorsement.

TB-500 (thymosin beta-4 fragment) has an even thinner human evidence base. Some anecdotal reports mention flu-like symptoms in the first few days of use. There is no mechanistic explanation for this that is well-supported, and it may reflect contaminated product rather than a true TB-500 effect.

GLP-1 Agonists: The Exception

The GLP-1 agonist class (semaglutide, tirzepatide, liraglutide) is the only peptide class covered on this site with substantial Grade A human safety data. The SUSTAIN and STEP trial series established the GI side effect profile comprehensively. Nausea occurs in approximately 40% of users at initiation; vomiting in 20%. Dose-escalation protocols — starting at 0.25mg weekly semaglutide for 4 weeks before increasing — were specifically designed to minimize these effects. Rare but serious risks include pancreatitis and, in rodent models, thyroid C-cell tumors (not replicated in humans to date).

The existence of robust human safety data for GLP-1 agonists does not transfer to other peptides. They are structurally and mechanistically distinct, and the human safety evidence for GLP-1s cannot be extrapolated to BPC-157, ipamorelin, or TB-500.